TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32711479
Drug: Matched control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matched control group with normal kidney function (estimated glomerular filtration rate ≥ 60 ml/min/1.73m²)
Study: 32712650
Drug: Number of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Number of metastatic treatments
Study: 32712650
Drug: Progesterone receptor
Normalized name: Progesterone receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone receptor negativity
Study: 32712806
Drug: Single-agent belantamab
Normalized name: belantamab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent belantamab mafodotin (2.5 mg/kg)
Study: 32714408
Drug: Compound Danshen
Normalized name: DANSHEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Compound Danshen dripping pills (CDDP)
Study: 32714423
Drug: Baduanjin sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baduanjin sequential therapy (BST) for 24 weeks
Study: 32715736
Drug: erenumab 70
Normalized name: Erenumab 70 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: erenumab 70 mg s.c. (every 28 days) for a total of three administrations
Study: 32715796
Drug: Auto-titrating continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auto-titrating continuous positive airway pressure (PAP) therapy initiated in 13 subjects who screened positive for OSA.
Study: 32716292
Drug: Higher-dose tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher-dose tigecycline (100 mg q12h) in CRRT group (7 cases)
Study: 32716292
Drug: Higher-dose tigecycline
Normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Higher-dose tigecycline (100 mg q12h) in non-CRRT group (9 cases)
Study: 36401942
Drug: Avelumab 10
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab 10 mg/kg intravenously every 2 weeks until hCG normalization, followed by 3 consolidation cycles
Study: 32716740
Drug: Actinomycin D
Normalized name: Actinomycin D
DrugBank: Dactinomycin (DB00970)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Actinomycin D or combination chemotherapy/surgery
Study: 32717365
Drug: Video capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video capsule endoscopy (VCE) in patients with DA
Study: 32717365
Drug: Video capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Video capsule endoscopy (VCE) in control patients (obscure GI bleeding or iron deficiency anemia)
Study: 32718723
Drug: Simplified index
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simplified index based on preoperative haemoglobin <120 g L.
Study: 32718906
Drug: Nivolumab 240
Normalized name: nivolumab 240 MG in 24 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 240 mg every 2 weeks (Q2W) for ≤24 months or until confirmed progression or unacceptable toxicity
Study: 32718926
Drug: Z-hypnotics
Normalized name: Z-160
DrugBank: Z-160 (DB12743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Z-hypnotics
Study: 32718997
Drug: Alpelisib (350
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpelisib (350 mg) combined with tamoxifen plus goserelin
Study: 32718997
Drug: Buparlisib (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buparlisib (100 mg) combined with tamoxifen plus goserelin
Study: 32719455
Drug: androgen receptor
Normalized name: Androgen receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: androgen receptor inhibitor with CDK4/6 inhibitor
Study: 32719455
Drug: PARP inhibitor
Normalized name: Poly (ADP-ribose) polymerase (PARP) inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: PARP inhibitor included
Study: 32719455
Drug: mTOR inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: mTOR inhibitor with nab-paclitaxel
Study: 38877477
Drug: Fentanyl buccal
Normalized name: Fentanyl Buccal Film
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl buccal soluble film (FBSF)
Study: 32721422
Drug: NIBB APBI
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIBB APBI using a dose of 34 Gy in 10 fractions delivered daily or twice a day.
Study: 32721954
Drug: Narsoplimab, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narsoplimab, a monoclonal antibody against MASP-2, dosage and duration not specified.
Study: 32723990
Drug: Asthma medication
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Asthma medication adherence assessment through patient interviews using four questions from the Malaysian Medication Adherence Scale.
Study: 32724669
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of OCT and fluorescein angiography imaging
Study: 32725444
Drug: Lanreotide autogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide autogel 120 mg at extended dosing intervals (>4 weeks)
Study: 32726419
Drug: Maribavir (400-1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maribavir (400-1200 mg twice daily)
Study: 32726554
Drug: Clobetasol propionate
Normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Clobetasol propionate 0.05% emollient foam applied daily
Study: 32728218
Drug: RNA vaccine
Normalized name: RSV mRNA vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: RNA vaccine
Study: 32728218
Drug: Checkpoint inhibitor
Normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Checkpoint inhibitor treatment
Study: 32729929
Drug: Nivolumab at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab at 3 mg/kg and Ipilimumab at 1 mg/kg every 3 weeks for 4 doses, followed by Nivolumab 3 mg/kg every 2 weeks for up to 96 weeks.
Study: 32730119
Drug: Pneumococcal conjugate
Normalized name: pneumococcal conjugate PCV 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pneumococcal conjugate vaccine (PCV) - 4 doses
Study: 32730187
Drug: Allogeneic stem
Normalized name: Allogeneic human mesenchymal stem cell
DrugBank: Remestemcel-L (DB13973)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic stem cell transplantation (SCT) after reinduction chemotherapy for very high risk and high risk patients.
Study: 32730187
Drug: Vinblastine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinblastine monotherapy for low risk patients (CD3-negative relapse > 1 year after initial diagnosis).
Study: 32730187
Drug: Vinblastine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinblastine monotherapy for intermediate risk patients after termination of autologous SCT.
Study: 32730187
Drug: Vinblastine monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinblastine monotherapy for early relapses.
Study: 32730586
Drug: AFM13 in
Normalized name: AFM13 (ANTI CD30 X ANTI CD16)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AFM13 in combination with pembrolizumab
Study: 32732023
Drug: Hypophosphataemia (phosphataemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypophosphataemia (phosphataemia below 0.8 mmol/L)
Study: 32732224
Drug: Vaccines targeting
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccines targeting a nondriver tumor-specific antigen or tumor neoepitopes
Study: 32733577
Drug: Standard treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatments combined with acupuncture therapy (electroacupuncture and scalp acupuncture) for a median course of five months
Study: 32733577
Drug: Standard treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatments combined with acupuncture therapy
Study: 32733600
Drug: Adalimumab 160/80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 160/80 mg at weeks 0/2 and 40 mg at weeks 4/6
Study: 32733600
Drug: Placebo at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo at weeks 0/2 followed by adalimumab 160/80 mg at weeks 4/6
Study: 32734176
Drug: Parenteral rotavirus
Normalized name: rotavirus vaccine, live attenuated, G1P[8] human 89-12 strain Oral Suspension [Rotarix]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral rotavirus vaccine
Study: 32734226
Drug: Immediate intensive
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate intensive nonsurgical periodontal treatment
Study: 32734226
Drug: Rescue treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue treatment for progressive disease
Study: 32734246
Drug: Exercise program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise program (resistance and aerobic exercise using exercise bands) with monthly consultations and 4 support calls over 12 weeks
Study: 32734251
Drug: Group-based care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group-based care (monthly sessions over 6 months)
Study: 32734695
Drug: Subcutaneous adipose
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous adipose tissue (SQAT) in women
Study: 32734695
Drug: Subcutaneous inflammatory
Normalized name: Arthriten Inflammatory Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous inflammatory gene expression
Study: 32735836
Drug: Selinexor (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selinexor (60 mg twice per week for 2 weeks, followed by 1 week off)
Study: 32736411
Drug: Sonidegib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sonidegib 800 mg QD
Study: 32737003
Drug: FOLFOX6 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX6 with cetuximab (500 mg/m2 biweekly)
Study: 32737087
Drug: Monthly subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly subcutaneous BUP-XR injections administered by a healthcare practitioner at intervals of 28 days (-2/+14 days) after a minimum of 7 days on 8-32 mg of sublingual buprenorphine (±naloxone)
Study: 32737087
Drug: Monthly subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monthly subcutaneous BUP-XR injections
Study: 32737088
Drug: Educational intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Educational intervention between prescribers and ASP leaders to reinforce proper use of novel antibiotics.
Study: 32737209
Drug: Treatment with
Normalized name: Campho-Phenique Cold Sore Treatment with Drying Action
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment with azithromycin or doxycycline
Study: 32737717
Drug: Cobimetinib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobimetinib (60 mg) and Ipatasertib (200 mg) in Arm A
Study: 32737717
Drug: Cobimetinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobimetinib (150 mg) and Ipatasertib (300 mg) in Arm B
Study: 32737717
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Cobimetinib and Ipatasertib
Study: 32738042
Drug: 45-mg subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45-mg subcutaneous leuprolide acetate (0.375 mL) at 0 and 24 weeks
Study: 32738905
Drug: Hypoglycemic agents
Normalized name: HYPOGLYCEMIC AGENTS,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoglycemic agents
Study: 32739654
Drug: Saizen® administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saizen® administered via easypod™
Study: 32740508
Drug: Glaucoma Treatment
Normalized name: ANTIGLAUCOMA,OTHER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glaucoma Treatment Compliance Assessment Tool (GTCAT)
Study: 32741045
Drug: Youth-directed goal
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Youth-directed goal setting incorporating blood glucose monitoring (BGM), continuous glucose monitoring (CGM), and insulin dosing
Study: 32741045
Drug: Sessions where
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sessions where goal intentions focused on BG only (without addressing insulin or CGM)
Study: 32741045
Drug: Sessions where
Normalized name: Alternanthera sessilis extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sessions where goal intentions focused on insulin dosing only (without addressing BGM or CGM)
Study: 32741971
Drug: LY3127804 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3127804 monotherapy (4, 8, 12, 16, 20 and 27 mg/kg)
Study: 32741971
Drug: LY3127804 (8,
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3127804 (8, 12, 16, 20 and 27 mg/kg) with 8 mg/kg ramucirumab
Study: 32741971
Drug: LY3127804 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3127804 (20 mg/kg) with 12 mg/kg ramucirumab
Study: 32741971
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (LY3127804 with ramucirumab)
Study: 32741971
Drug: LY3127804 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY3127804 20 mg/kg
Study: 32742241
Drug: Biotin-labeled molecular
Normalized name: Molecular AF
DrugBank: Tolnaftate (DB00525)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biotin-labeled molecular probes comprising specific regions of the SARS-CoV-2 spike; yields from transient transfection ranged from ~0.5 mg/L for the complete ectodomain to >5 mg/L for several subregions.
Study: 32742241
Drug: Biotinylated probes;
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biotinylated probes; characterized for antibody-binding specificities and cell-sorting capabilities.
Study: 32742443
Drug: Concurrent chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent chemoradiotherapy with oral etoposide and cisplatin
Study: 32742711
Drug: Biosimilar recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biosimilar recombinant follicle stimulating hormone (rFSH)
Study: 32743011
Drug: Intra-articular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular administration of Tranexamic Acid (TXA) 100 mL (30 mg/mL)
Study: 32743011
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no IA injection of TXA)
Study: 32743011
Drug: Intra-articular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular administration of Tranexamic Acid (TXA)
Study: 32743852
Drug: Antihypertensives
Normalized name: ANTIHYPERTENSIVES
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensives
Study: 32743852
Drug: Medication adherence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication adherence (self-reported)
Study: 32744105
Drug: Lipid-lowering treatment
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering treatment in patients with definite/probable FH
Study: 32745961
Drug: ssCART-19s (CAR-T
Approvals — FDA: no, EMA: no, PMDA: no
Description: ssCART-19s (CAR-T therapy targeting CD19 with shRNA-IL-6 gene silencing)
Study: 32747357
Drug: cAMB administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: cAMB administered at 1.0 g per day
Study: 32747357
Drug: cAMB administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: cAMB administered at 1.5 g per day
Study: 32747357
Drug: cAMB administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: cAMB administered at 2.0 g per day
Study: 32748658
Drug: Daily activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily activity energy expenditure
Study: 32749224
Drug: Active control
Normalized name: Accu-Chek Active Control Solution
DrugBank: Pyrithione (DB06815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active control condition (3 times weekly emotion reporting).
Study: 32749710
Drug: DAA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAA treatment (direct-acting antivirals)
Study: 32753543
Drug: Checkpoint inhibitor
Normalized name: Anti-tim3 checkpoint inhibitor mbg453
DrugBank: Sabatolimab (DB16322)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Checkpoint inhibitor therapy (CIT)
Study: 32753546
Drug: CC-486 300
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-486 300 mg QD Days 1-14 (cycles 1-3 only) + durvalumab 1500 mg IV day 15 (regimen A)
Study: 32753546
Drug: CC-486 100
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-486 100 mg QD days 1-21 + vitamin C 500 mg once a day continuously + durvalumab 1500 mg IV day 15 (regimen B)
Study: 32753849
Drug: Long-acting injectable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting injectable (LAI) antipsychotics
Study: 32753849
Drug: Deltoid injection
Normalized name: Ambrosia deltoidea pollen
DrugBank: Ambrosia deltoidea pollen (DB10765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deltoid injection
Study: 32753849
Drug: 3-monthly dosing
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3-monthly dosing
Study: 32753875
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment with any FDA approved or cleared device
Study: 32753879
Drug: pyrotinib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: pyrotinib (400 mg po qd)
Study: 32754110
Drug: Tasimelteon (HETLIOZ®);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tasimelteon (HETLIOZ®); dosage and duration not available
Study: 32754110
Drug: Placebo; dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo; dosage and duration not available
Study: 32755471
Drug: Chronic oral
Normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chronic oral nitrite therapy (40 mg/3× daily)
Study: 32755608
Drug: Pharmacological stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological stimulation targeting β2-adrenergic receptors (β2-AR); specific dosage and duration not mentioned.
Study: 32756984
Drug: Oral anti-coagulation
Normalized name: anti-inhibitor coagulant complex
DrugBank: Anti-inhibitor coagulant complex (DB13151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anti-coagulation
Study: 32757642
Drug: PA pressure-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: PA pressure-guided therapy
Study: 32757824
Drug: L-alone (8-session
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-alone (8-session diet and physical activity lifestyle intervention)
Study: 32757824
Drug: L+Sleep (L-alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: L+Sleep (L-alone plus a behavioral sleep intervention)
Study: 32757824
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (L-alone and L+Sleep)
Study: 32758188
Drug: Postoperative stereotactic
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative stereotactic body radiotherapy (SBRT) with a total dose of 36 Gy in 6 fractions over 2 weeks
Study: 32758434
Drug: Avadomide (3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avadomide (3.0 mg as formulated capsules) plus Obinutuzumab (1000 mg)
Study: 32758434
Drug: Avadomide (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avadomide (various doses) plus Obinutuzumab (1000 mg)
Study: 32758438
Drug: Health-care workers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health-care workers screened for IgM and IgG antibodies against SARS-CoV-2
Study: 32759300
Drug: Serum HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum HBV RNA ≥44.6 U/mL
Study: 32759300
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of HBV RNA undetectability and HBsAg <10 IU/mL
Study: 32759300
Drug: Off-treatment ALT
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: Off-treatment ALT elevation
Study: 32760832
Drug: Lithium (150-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (150-300 mg/daily)
Study: 32761088
Drug: Thyroid hormone
Normalized name: Thyroid hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid hormone supplementation after 20 weeks (median TSH 0.03 mU/L)
Study: 32761122
Drug: DAA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAA treatment for replicating HCV infections
Study: 32761864
Drug: Cumulative heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cumulative heparin dose
Study: 32762458
Drug: GlycA (375
Approvals — FDA: no, EMA: no, PMDA: no
Description: GlycA (375 μmol/L mean)
Study: 32762662
Drug: Intraoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraoperative radiation therapy (IORT) combined with external beam radiotherapy (EBRT)
Study: 32763882
Drug: Point-of-care HIV-1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point-of-care HIV-1 RNA testing combined with standard rapid antibody tests; 12 months follow-up for clinical outcomes.
Study: 32763967
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment arm (control)
Study: 32764775
Drug: High-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose aspirin (> 100 up to 325 mg daily)
Study: 32764775
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin (≤ 100 mg daily)
Study: 32765053
Drug: Standard analgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard analgesic treatment (SAT; IV paracetamol 1 g or ketoprofen 100 mg for moderate pain [NRS 4-6] and IV morphine 0.1mg/kg for severe pain [NRS ≥7])
Study: 32765053
Drug: Standard analgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard analgesic treatment (SAT)
Study: 32765056
Drug: Mirogabalin (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirogabalin (7.5 mg twice daily for moderate renal impairment; 7.5 mg once daily for severe renal impairment)
Study: 32765156
Drug: Subspecialist treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subspecialist treatment for severe asthma
Study: 32766469
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of nerve growth factor (NGF) into the right masseter muscle on days 0 and 2.
Study: 32766469
Drug: Pain diaries
Normalized name: Dermoplast Pain
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain diaries completed twice daily from day 0 to day 30.
Study: 32766725
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of ciprofloxacin 500 mg
Study: 32766875
Drug: Avelumab 10
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab 10 mg/kg on days 1 and 15 of a 28-day cycle